270 related articles for article (PubMed ID: 20450197)
1. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
2. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
[TBL] [Abstract][Full Text] [Related]
4. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
6. Particle swarm optimization and genetic algorithm as feature selection techniques for the QSAR modeling of imidazo[1,5-a]pyrido[3,2-e]pyrazines, inhibitors of phosphodiesterase 10A.
Goodarzi M; Saeys W; Deeb O; Pieters S; Vander Heyden Y
Chem Biol Drug Des; 2013 Dec; 82(6):685-96. PubMed ID: 23906083
[TBL] [Abstract][Full Text] [Related]
7. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
[TBL] [Abstract][Full Text] [Related]
8. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
Banerjee A; Narayana L; Raje FA; Pisal DV; Kadam PA; Gullapalli S; Kumar H; More SV; Bajpai M; Sangana RR; Jadhav S; Gudi GS; Khairatkar-Joshi N; Merugu RR; Voleti SR; Gharat LA
Bioorg Med Chem Lett; 2013 Dec; 23(24):6747-54. PubMed ID: 24231362
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
[TBL] [Abstract][Full Text] [Related]
11. Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors.
Geneste H; Drescher K; Jakob C; Laplanche L; Ochse M; Torrent M
Bioorg Med Chem Lett; 2019 Feb; 29(3):406-412. PubMed ID: 30587449
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors.
Hu E; Kunz RK; Rumfelt S; Chen N; Bürli R; Li C; Andrews KL; Zhang J; Chmait S; Kogan J; Lindstrom M; Hitchcock SA; Treanor J
Bioorg Med Chem Lett; 2012 Mar; 22(6):2262-5. PubMed ID: 22365755
[TBL] [Abstract][Full Text] [Related]
14. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
15. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
18. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
Kulkarni SS; Patel MR; Talele TT
Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.
Bartolomé-Nebreda JM; Alonso de Diego SA; Artola M; Delgado F; Delgado Ó; Martín-Martín ML; Martínez-Viturro CM; Pena MÁ; Tong HM; Van Gool M; Alonso JM; Fontana A; Macdonald GJ; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2015 Jan; 58(2):978-93. PubMed ID: 25495129
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]